Tumor Cells Require Thymidylate Kinase to Prevent dUTP Incorporation during DNA Repair
Journal
Cancer Cell
Journal Volume
22
Journal Issue
1
Pages
36-50
Date Issued
2012
Author(s)
Hu C.-M.
Yeh M.-T.
Tsao N.
Chen C.-W.
Gao Q.-Z.
Chang C.-Y.
Lee M.-H.
Fang J.-M.
Sheu S.-Y.
Lin C.-J.
Tseng M.-C.
Chen Y.-J.
Abstract
The synthesis of dTDP is unique because there is a requirement for thymidylate kinase (TMPK). All other dNDPs including dUDP are directly produced by ribonucleotide reductase (RNR). We report the binding of TMPK and RNR at sites of DNA damage. In tumor cells, when TMPK function is blocked, dUTP is incorporated during DNA double-strand break (DSB) repair. Disrupting RNR recruitment to damage sites or reducing the expression of the R2 subunit of RNR prevents the impairment of DNA repair by TMPK intervention, indicating that RNR contributes to dUTP incorporation during DSB repair. We identified a cell-permeable nontoxic inhibitor of TMPK that sensitizes tumor cells to doxorubicin in vitro and in vivo, suggesting its potential as a therapeutic option. ? 2012 Elsevier Inc..
SDGs
Other Subjects
antineoplastic agent; deoxyuridine triphosphate pyrophosphatase; doxorubicin; ethyl 4 (2 (4,6 dimethyl 3 oxoisothiazolo[5,4 b]pyridin 2(3h) yl)acetyl)piperazine 1 carboxylate; histone H2AX; phosphotransferase; phosphotransferase inhibitor; ribonucleotide reductase; thymidylate kinase; unclassified drug; YMU1; animal experiment; animal model; animal tissue; antineoplastic activity; article; cancer cell; cell growth; controlled study; DNA repair; double stranded DNA break; drug sensitization; drug synthesis; enzyme binding; gene silencing; human; human cell; IC 50; in vitro study; in vivo study; mouse; nonhuman; priority journal; protein expression; tumor growth; tumor volume; tumor xenograft
Type
journal article